Animal models of bipolar mania: The past, present and future

Neuroscience

Volumn 321, Issue , 2016, Pages 163-188

  Logan, R W ^a   McClung, C A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Bipolar disorder; Circadian rhythms; Genetics; Mania; Mood stabilizers

Indexed keywords

ACETYLCYSTEINE; AMPHETAMINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLOZAPINE; ETIRACETAM; HALOPERIDOL; LAMOTRIGINE; LITHIUM SALT; MELATONIN; METIROSINE; MODAFINIL; OUABAIN; QUETIAPINE; QUINPIROLE; RETIGABINE; VALPROIC ACID; VANOXERINE; ANTIDEPRESSANT AGENT; TRANQUILIZER;

ANHEDONIA; ANIMAL MODEL; ANXIETY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CONSTRUCT VALIDITY; DEPRESSION; DISABILITY; ENERGY; FACE VALIDITY; GENETICALLY ENGINEERED MOUSE STRAIN; HELPLESSNESS; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INCIDENCE; MANIA; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REVIEW; SLEEP; ANIMAL; DISEASE MODEL; MOUSE; TRANSGENIC MOUSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC;

EID: 84940883083     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.08.041     Document Type: Review

References (310)

1. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997, 16:3797-3804.
2. Adida M., Clark L., Pomietto P., Kaladjian A., Besnier N., Azorin J.M., Jeanningros R., Goodwin G.M. Lack of insight may predict impaired decision making in manic patients. Bipolar Disord 2008, 10:829-837.
3. Amsterdam J.D., Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression-lack of manic induction. J Affect Disord 2005, 87:121-130.
4. Anand A., Darnell A., Miller H.L., Berman R.M., Cappiello A., Oren D.A., Woods S.W., Charney D.S. Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. Biol Psychiatry 1999, 45:972-978.
5. Anand A., Barkay G., Dzemidzic M., Albrecht D., Karne H., Zheng Q.H., Hutchins G.D., Normandin M.D., Yoder K.K. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord 2011, 13:406-413.
6. Antoch M.P., Song E.J., Chang A.M., Vitaterna M.H., Zhao Y., Wilsbacher L.D., Sangoram A.M., King D.P., Pinto L.H., Takahashi J.S. Functional identification of the mouse circadian Clock gene by transgenic BAC rescue. Cell 1997, 89:655-667.
7. Arban R., Maraia G., Brackenborough K., Winyard L., Wilson A., Gerrard P., Large C. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res 2005, 158:123-132.
8. Arent C.O., Valvassori S.S., Fries G.R., Stertz L., Ferreira C.L., Lopes-Borges J., Mariot E., Varela R.B., Ornell F., Kapczinski F., Andersen M.L., Quevedo J. Neuroanatomical profile of antimaniac effects of histone deacetylases inhibitors. Mol Neurobiol 2011, 43:207-214.
9. Arey R.N., Enwright J.F., Spencer S.M., Falcon E., Ozburn A.R., Ghose S., Tamminga C., McClung C.A. An important role for cholecystokinin, a CLOCK target gene, in the development and treatment of manic-like behaviors. Mol Psychiatry 2014, 19:342-350.
10. Ashkenazy T., Einat H., Kronfeld-Schor N. Effects of bright light treatment on depression- and anxiety-like behaviors of diurnal rodents maintained on a short daylight schedule. Behav Brain Res 2009, 201:343-346.
11. Azorin J.M., Sapin C., Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord 2013, 145:62-69.
12. Bagot R.C., Labonte B., Pena C.J., Nestler E.J. Epigenetic signaling in psychiatric disorders: stress and depression. Dialogues Clin Neurosci 2014, 16:281-295.
13. Barrett S.L., Kelly C., Watson D.R., Bell R., King D.J. Normal levels of prepulse inhibition in the euthymic phase of bipolar disorder. Psychol Med 2005, 35:1737-1746.
14. Beaulieu J.M. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci 2012, 37:7-16.
15. Beaulieu J.M., Del'guidice T., Sotnikova T.D., Lemasson M., Gainetdinov R.R. Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors. Front Mol Neurosci 2011, 4:38.
16. Bechara A., Damasio A.R., Damasio H., Anderson S.W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 1994, 50:7-15.
17. Bechara A., Damasio H., Tranel D., Damasio A.R. Deciding advantageously before knowing the advantageous strategy. Science 1997, 275:1293-1295.
18. Bechara A., Damasio H., Tranel D., Damasio A.R. The Iowa Gambling Task and the somatic marker hypothesis: some questions and answers. Trends Cogn Sci 2005, 9:159-162. discussion 162-154.
19. Behrens J., Jerchow B.A., Wurtele M., Grimm J., Asbrand C., Wirtz R., Kuhl M., Wedlich D., Birchmeier W. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998, 280:596-599.
20. Benedetti F., Serretti A., Colombo C., Barbini B., Lorenzi C., Campori E., Smeraldi E. Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet B Neuropsychiatr Genet 2003, 123B:23-26.
21. Benedetti F., Fresi F., Maccioni P., Smeraldi E. Behavioural sensitization to repeated sleep deprivation in a mice model of mania. Behav Brain Res 2008, 187:221-227.
22. Benes F.M. Searching for unique endophenotypes for schizophrenia and bipolar disorder within neural circuits and their molecular regulatory mechanisms. Schizophr Bull 2007, 33:932-936.
23. Bennett V., Lambert S. Physiological roles of axonal ankyrins in survival of premyelinated axons and localization of voltage-gated sodium channels. J Neurocytol 1999, 28:303-318.
24. Berggren U., Tallstedt L., Ahlenius S., Engel J. The effect of lithium on amphetamine-induced locomotor stimulation. Psychopharmacology 1978, 59:41-45.
25. Berk M., Dean O.M., Cotton S.M., Gama C.S., Kapczinski F., Fernandes B., Kohlmann K., Jeavons S., Hewitt K., Moss K., Allwang C., Schapkaitz I., Cobb H., Bush A.I., Dodd S., Malhi G.S. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med 2012, 10:91.
26. Besing R.C., Paul J.R., Hablitz L.M., Rogers C.O., Johnson R.L., Young M.E., Gamble K.L. Circadian rhythmicity of active GSK3 isoforms modulates molecular clock gene rhythms in the suprachiasmatic nucleus. J Biol Rhythms 2015, 30:155-160.
27. Boland E.M., Bender R.E., Alloy L.B., Conner B.T., Labelle D.R., Abramson L.Y. Life events and social rhythms in bipolar spectrum disorders: an examination of social rhythm sensitivity. J Affect Disord 2012, 139:264-272.
28. Brain P.F., Al-Maliki S. Effects of lithium chloride injections on rank-related fighting, maternal aggression and locust-killing responses in naive and experienced 'TO' strain mice. Pharmacol Biochem Behav 1979, 10:663-669.
29. Bunney W.E., Kopanda R.T., Murphy D.L. Sleep and behavioral changes possibly reflecting central receptor hypersensitivity following catecholamine synthesis inhibition in man. Acta Psychiatr Scand 1977, 56:189-203.
30. Burdick K.E., Goldberg T.E., Cornblatt B.A., Keefe R.S., Gopin C.B., Derosse P., Braga R.J., Malhotra A.K. The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology 2011, 36:1587-1592.
31. Cabungcal J.H., Nicolas D., Kraftsik R., Cuenod M., Do K.Q., Hornung J.P. Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol Dis 2006, 22:624-637.
32. Calil H.M., Zwicker A.P., Klepacz S. The effects of lithium carbonate on healthy volunteers: mood stabilization?. Biol Psychiatry 1990, 27:711-722.
33. Can A., Schulze T.G., Gould T.D. Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav 2014, 123:3-16.
34. Cappeliez P., Moore E. Effects of lithium on an amphetamine animal model of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 1990, 14:347-358.
35. Carlezon W.A., Chartoff E.H. Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2007, 2:2987-2995.
36. Carroll C.A., Vohs J.L., O'Donnell B.F., Shekhar A., Hetrick W.P. Sensorimotor gating in manic and mixed episode bipolar disorder. Bipolar Disord 2007, 9:221-229.
37. Challet E., Takahashi J.S., Turek F.W. Nonphotic phase-shifting in clock mutant mice. Brain Res 2000, 859:398-403.
38. Chen G., Huang L.D., Jiang Y.M., Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999, 72:1327-1330.
39. Chen G., Henter I.D., Manji H.K. Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry 2010, 15:883-895.
40. Chesler E.J., Logan R.W. Opportunities for bioinformatics in the classification of behavior and psychiatric disorders. Int Rev Neurobiol 2012, 104:183-211.
41. Christodoulou T., Lewis M., Ploubidis G.B., Frangou S. The relationship of impulsivity to response inhibition and decision-making in remitted patients with bipolar disorder. Eur Psychiatry 2006, 21:270-273.
42. Chubb J.E., Bradshaw N.J., Soares D.C., Porteous D.J., Millar J.K. The DISC locus in psychiatric illness. Mol Psychiatry 2008, 13:36-64.
43. Clapcote S.J., Duffy S., Xie G., Kirshenbaum G., Bechard A.R., Rodacker Schack V., Petersen J., Sinai L., Saab B.J., Lerch J.P., Minassian B.A., Ackerley C.A., Sled J.G., Cortez M.A., Henderson J.T., Vilsen B., Roder J.C. Mutation I810N in the alpha3 isoform of Na+, K+-ATPase causes impairments in the sodium pump and hyperexcitability in the CNS. Proc Natl Acad Sci USA 2009, 106:14085-14090.
44. Clark L., Iversen S.D., Goodwin G.M. A neuropsychological investigation of prefrontal cortex involvement in acute mania. Am J Psychiatry 2001, 158:1605-1611.
45. Cole T.B., Giordano G., Co A.L., Mohar I., Kavanagh T.J., Costa L.G. Behavioral characterization of GCLM-knockout mice, a model for enhanced susceptibility to oxidative stress. J Toxicol 2011, 2011:157687.
46. Coque L., Mukherjee S., Cao J.L., Spencer S., Marvin M., Falcon E., Sidor M.M., Birnbaum S.G., Graham A., Neve R.L., Gordon E., Ozburn A.R., Goldberg M.S., Han M.H., Cooper D.C., McClung C.A. Specific role of VTA dopamine neuronal firing rates and morphology in the reversal of anxiety-related, but not depression-related behavior in the ClockDelta19 mouse model of mania. Neuropsychopharmacology 2011, 36:1478-1488.
47. Cousins D.A., Butts K., Young A.H. The role of dopamine in bipolar disorder. Bipolar Disord 2009, 11:787-806.
48. Crowley J.J., Kim Y., Lenarcic A.B., Quackenbush C.R., Barrick C.J., Adkins D.E., Shaw G.S., Miller D.R., de Villena F.P., Sullivan P.F., Valdar W. Genetics of adverse reactions to haloperidol in a mouse diallel: a drug-placebo experiment and Bayesian causal analysis. Genetics 2014, 196:321-347.
49. de Bartolomeis A., Buonaguro E.F., Iasevoli F., Tomasetti C. The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment. J Psychopharmacol 2014, 28:505-526.
50. De Sarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002, 43:1158-1164.
51. de Visser L., Homberg J.R., Mitsogiannis M., Zeeb F.D., Rivalan M., Fitoussi A., Galhardo V., van den Bos R., Winstanley C.A., Dellu-Hagedorn F. Rodent versions of the Iowa gambling task: opportunities and challenges for the understanding of decision-making. Front Neurosci 2011, 5:109.
52. De Wilde J.E., Doogan D.P. Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 1982, 4:249-259.
53. Dean O.M., van den Buuse M., Bush A.I., Copolov D.L., Ng F., Dodd S., Berk M. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 2009, 16:2965-2976.
54. Dean O.M., van den Buuse M., Berk M., Copolov D.L., Mavros C., Bush A.I. N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci Lett 2011, 499:149-153.
55. Decker S., Grider G., Cobb M., Li X.P., Huff M.O., El-Mallakh R.S., Levy R.S. Open field is more sensitive than automated activity monitor in documenting ouabain-induced hyperlocomotion in the development of an animal model for bipolar illness. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:455-462.
56. Dencker D., Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav Brain Res 2010, 207:78-83.
57. Dencker D., Dias R., Pedersen M.L., Husum H. Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy Behav 2008, 12:49-53.
58. Dick D.M., Foroud T., Flury L., Bowman E.S., Miller M.J., Rau N.L., Moe P.R., Samavedy N., El-Mallakh R., Manji H., Glitz D.A., Meyer E.T., Smiley C., Hahn R., Widmark C., McKinney R., Sutton L., Ballas C., Grice D., Berrettini W., Byerley W., Coryell W., DePaulo R., MacKinnon D.F., Gershon E.S., Kelsoe J.R., McMahon F.J., McInnis M., Murphy D.L., Reich T., Scheftner W., Nurnberger J.I. Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. Am J Hum Genet 2003, 73:107-114.
59. Dietz R.M., Kiedrowski L., Shuttleworth C.W. Contribution of Na(+)/Ca(2+) exchange to excessive Ca(2+) loading in dendrites and somata of CA1 neurons in acute slice. Hippocampus 2007, 17:1049-1059.
60. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003, 116:1175-1186.
61. Dulcis D., Jamshidi P., Leutgeb S., Spitzer N.C. Neurotransmitter switching in the adult brain regulates behavior. Science 2013, 340:449-453.
62. Durak O., de Anda F.C., Singh K.K., Leussis M.P., Petryshen T.L., Sklar P., Tsai L.H. Ankyrin-G regulates neurogenesis and Wnt signaling by altering the subcellular localization of beta-catenin. Mol Psychiatry 2015, 20:388-397.
63. Dwivedi T., Zhang H. Lithium-induced neuroprotection is associated with epigenetic modification of specific BDNF gene promoter and altered expression of apoptotic-regulatory proteins. Front Neurosci 2014, 8:457.
64. Dzirasa K., Coque L., Sidor M.M., Kumar S., Dancy E.A., Takahashi J.S., McClung C.A., Nicolelis M.A. Lithium ameliorates nucleus accumbens phase-signaling dysfunction in a genetic mouse model of mania. J Neurosci 2010, 30:16314-16323.
65. Dzirasa K., McGarity D.L., Bhattacharya A., Kumar S., Takahashi J.S., Dunson D., McClung C.A., Nicolelis M.A. Impaired limbic gamma oscillatory synchrony during anxiety-related behavior in a genetic mouse model of bipolar mania. J Neurosci 2011, 31:6449-6456.
66. Easton A., Arbuzova J., Turek F.W. The circadian Clock mutation increases exploratory activity and escape-seeking behavior. Genes Brain Behav 2003, 2:11-19.
67. Ehlers C.L., Frank E., Kupfer D.J. Social zeitgebers and biological rhythms. A unified approach to understanding the etiology of depression. Arch Gen Psychiatry 1988, 45:948-952.
68. Eichelman B., Thoa N.B., Perez-Cruet J. Alkali metal cations: effects on aggression and adrenal enzymes. Pharmacol Biochem Behav 1973, 1:121-123.
69. Einat H. Modelling facets of mania - new directions related to the notion of endophenotypes. J Psychopharmacol 2006, 20:714-722.
70. Einat H. Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease. Behav Genet 2007, 37:244-255.
71. Einat H., Kronfeld-Schor N., Eilam D. Sand rats see the light: short photoperiod induces a depression-like response in a diurnal rodent. Behav Brain Res 2006, 173:153-157.
72. Ellicott A., Hammen C., Gitlin M., Brown G., Jamison K. Life events and the course of bipolar disorder. Am J Psychiatry 1990, 147:1194-1198.
73. el-Mallakh R.S., Harrison L.T., Li R., Changaris D.G., Levy R.S. An animal model for mania: preliminary results. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:955-962.
74. El-Mallakh R.S., Decker S., Morris M., Li X.P., Huff M.O., El-Masri M.A., Levy R.S. Efficacy of olanzapine and haloperidol in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1261-1264.
75. Ene H.M., Kara N.Z., Einat H. The effects of the atypical antipsychotic asenapine in a strain-specific battery of tests for mania-like behaviors. Behav Pharmacol 2015.
76. Engel S.R., Creson T.K., Hao Y., Shen Y., Maeng S., Nekrasova T., Landreth G.E., Manji H.K., Chen G. The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Mol Psychiatry 2009, 14:448-461.
77. Etain B., Jamain S., Milhiet V., Lajnef M., Boudebesse C., Dumaine A., Mathieu F., Gombert A., Ledudal K., Gard S., Kahn J.P., Henry C., Boland A., Zelenika D., Lechner D., Lathrop M., Leboyer M., Bellivier F. Association between circadian genes, bipolar disorders and chronotypes. Chronobiol Int 2014, 31:807-814.
78. Evenden J. Impulsivity: a discussion of clinical and experimental findings. J Psychopharmacol 1999, 13:180-192.
79. Fessler R.G., Sturgeon R.D., London S.F., Meltzer H.Y. Effects of lithium on behaviour induced by phencyclidine and amphetamine in rats. Psychopharmacology 1982, 78:373-376.
80. Flaisher-Grinberg S., Einat H. Strain-specific battery of tests for domains of mania: effects of valproate, lithium and imipramine. Front Psychiatry 2010, 1:10.
81. Flaisher-Grinberg S., Kronfeld-Schor N., Einat H. Models of mania: from facets to domains and from animal models to model animals. J Psychopharmacol 2010, 24:437-438.
82. Frangou S., Kington J., Raymont V., Shergill S.S. Examining ventral and dorsal prefrontal function in bipolar disorder: a functional magnetic resonance imaging study. Eur Psychiatry 2008, 23:300-308.
83. Frank E., Swartz H.A., Kupfer D.J. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry 2000, 48:593-604.
84. Frank E., Soreca I., Swartz H.A., Fagiolini A.M., Mallinger A.G., Thase M.E., Grochocinski V.J., Houck P.R., Kupfer D.J. The role of interpersonal and social rhythm therapy in improving occupational functioning in patients with bipolar I disorder. Am J Psychiatry 2008, 165:1559-1565.
85. Fries G.R., Valvassori S.S., Bock H., Stertz L., Magalhaes P.V., Mariot E., Varela R.B., Kauer-Sant'Anna M., Quevedo J., Kapczinski F., Saraiva-Pereira M.L. Memory and brain-derived neurotrophic factor after subchronic or chronic amphetamine treatment in an animal model of mania. J Psychiatr Res 2015.
86. Gardner R. Mechanisms in manic-depressive disorder: an evolutionary model. Arch Gen Psychiatry 1982, 39:1436-1441.
87. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Yatham L.N., Young L.T. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int J Neuropsychopharmacol 2011, 14:1069-1074.
88. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011, 14:123-130.
89. Geoffroy P.A., Bellivier F., Scott J., Boudebesse C., Lajnef M., Gard S., Kahn J.P., Azorin J.M., Henry C., Leboyer M., Etain B. Bipolar disorder with seasonal pattern: clinical characteristics and gender influences. Chronobiol Int 2013, 30:1101-1107.
90. Gessa G.L., Pani L., Fadda P., Fratta W. Sleep deprivation in the rat: an animal model of mania. Eur Neuropsychopharmacol 1995, 5(Suppl):89-93.
91. Geyer M.A., Russo P.V., Masten V.L. Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 1986, 25:277-288.
92. Giakoumaki S.G., Bitsios P., Frangou S., Roussos P., Aasen I., Galea A., Kumari V. Low baseline startle and deficient affective startle modulation in remitted bipolar disorder patients and their unaffected siblings. Psychophysiology 2010, 47:659-668.
93. Gijsman H.J., Geddes J.R., Rendell J.M., Nolen W.A., Goodwin G.M. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004, 161:1537-1547.
94. Gogos A., van den Buuse M., Rossell S. Gender differences in prepulse inhibition (PPI) in bipolar disorder: men have reduced PPI, women have increased PPI. Int J Neuropsychopharmacol 2009, 12:1249-1259.
95. Goldberg J.F., Burdick K.E. Levetiracetam for acute mania. Am J Psychiatry 2002, 159:148.
96. Goldstein I., Lerer E., Laiba E., Mallet J., Mujaheed M., Laurent C., Rosen H., Ebstein R.P., Lichtstein D. Association between sodium- and potassium-activated adenosine triphosphatase alpha isoforms and bipolar disorders. Biol Psychiatry 2009, 65:985-991.
97. Goldstein T.R., Fersch-Podrat R., Axelson D.A., Gilbert A., Hlastala S.A., Birmaher B., Frank E. Early intervention for adolescents at high risk for the development of bipolar disorder: pilot study of Interpersonal and Social Rhythm Therapy (IPSRT). Psychotherapy 2014, 51:180-189.
98. Gomez-Sintes R., Bortolozzi A., Artigas F., Lucas J.J. Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice. Eur Neuropsychopharmacol 2014, 24:1524-1533.
99. Gonzalez J.M., Thompson P.M., Moore T.A. Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. Patient Prefer Adherence 2011, 5:333-341.
100. Gonzalez R., Bernardo C., Cruz D., Walss-Bass C., Thompson P.M. The relationships between clinical characteristics, alcohol and psychotropic exposure, and circadian gene expression in human postmortem samples of affective disorder and control subjects. Psychiatry Res 2014, 218:359-362.
101. Gould T.D., Manji H.K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005, 30:1223-1237.
102. Gould T.J., Keith R.A., Bhat R.V. Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav Brain Res 2001, 118:95-105.
103. Gould T.D., Quiroz J.A., Singh J., Zarate C.A., Manji H.K. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004, 9:734-755.
104. Gould T.D., O'Donnell K.C., Picchini A.M., Manji H.K. Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 2007, 32:1321-1333.
105. Gray C.M., McCormick D.A. Chattering cells: superficial pyramidal neurons contributing to the generation of synchronous oscillations in the visual cortex. Science 1996, 274:109-113.
106. Green M.F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006, 67(Suppl. 9):3-8. discussion 36-42.
107. Greenwood T.A., Schork N.J., Eskin E., Kelsoe J.R. Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples. Mol Psychiatry 2006, 11(125-133):115.
108. Grisar T., Guillaume D., Delgado-Escueta A.V. Contribution of Na+, K(+)-ATPase to focal epilepsy: a brief review. Epilepsy Res 1992, 12:141-149.
109. Grunze H., Langosch J., Born C., Schaub G., Walden J. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 2003, 64:781-784.
110. Guilmatre A., Huguet G., Delorme R., Bourgeron T. The emerging role of SHANK genes in neuropsychiatric disorders. Dev Neurobiol 2014, 74:113-122.
111. Gustafson C.L., Partch C.L. Emerging models for the molecular basis of mammalian circadian timing. Biochemistry 2015, 54:134-149.
112. Han K., Holder J.L., Schaaf C.P., Lu H., Chen H., Kang H., Tang J., Wu Z., Hao S., Cheung S.W., Yu P., Sun H., Breman A.M., Patel A., Lu H.C., Zoghbi H.Y. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 2013, 503:72-77.
113. Hannah-Poquette C., Anderson G.W., Flaisher-Grinberg S., Wang J., Meinerding T.M., Einat H. Modeling mania: further validation for Black Swiss mice as model animals. Behav Brain Res 2011, 223:222-226.
114. Hashimoto K. BDNF and proBDNF as biomarkers for bipolar disorder. Br J Psychiatry 2014, 205:410.
115. Henry B.L., Minassian A., Young J.W., Paulus M.P., Geyer M.A., Perry W. Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev 2010, 34:1296-1306.
116. Hicks R.A., Moore J.D. REM sleep deprivation diminishes fear in rats. Physiol Behav 1979, 22:689-692.
117. Hicks R.A., Moore J.D., Hayes C., Phillips N., Hawkins J. REM sleep deprivation increases aggressiveness in male rats. Physiol Behav 1979, 22:1097-1100.
118. Himmelhoch J.M., Fuchs C.Z., Symons B.J. A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 1982, 170:628-634.
119. Hlastala S.A. Stress, social rhythms, and behavioral activation: psychosocial factors and the bipolar illness course. Curr Psychiatry Rep 2003, 5:477-483.
120. Homberg J.R., van den Bos R., den Heijer E., Suer R., Cuppen E. Serotonin transporter dosage modulates long-term decision-making in rat and human. Neuropharmacology 2008, 55:80-84.
121. Horschitz S., Hummerich R., Lau T., Rietschel M., Schloss P. A dopamine transporter mutation associated with bipolar affective disorder causes inhibition of transporter cell surface expression. Mol Psychiatry 2005, 10:1104-1109.
122. Houtepen L.C., Boks M.P., Kahn R.S., Joels M., Vinkers C.H. Antipsychotic use is associated with a blunted cortisol stress response: a study in euthymic bipolar disorder patients and their unaffected siblings. Eur Neuropsychopharmacol 2015, 25:77-84.
123. Jacobsen J.P., Rodriguiz R.M., Mork A., Wetsel W.C. Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia?. Neuroscience 2005, 132:1055-1072.
124. Jiang W.G., Li S.X., Liu J.F., Sun Y., Zhou S.J., Zhu W.L., Shi J., Lu L. Hippocampal CLOCK protein participates in the persistence of depressive-like behavior induced by chronic unpredictable stress. Psychopharmacology 2013, 227:79-92.
125. Jin N., Kovacs A.D., Sui Z., Dewhurst S., Maggirwar S.B. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology 2005, 48:576-583.
126. Jochum T., Bar K.J., Sauer H. Topiramate induced manic episode. J Neurol Neurosurg Psychiatry 2002, 73:208-209.
127. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006, 7:1421-1434.
128. Jornada L.K., Valvassori S.S., Arent C.O., Leffa D., Damiani A.A., Hainzenreder G., Ferreira C.L., Moretti M., Andrade V.M., Quevedo J. DNA damage after intracerebroventricular injection of ouabain in rats. Neurosci Lett 2010, 471:6-9.
129. Jornada L.K., Valvassori S.S., Steckert A.V., Moretti M., Mina F., Ferreira C.L., Arent C.O., Dal-Pizzol F., Quevedo J. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J Psychiatr Res 2011, 45:162-168.
130. Joyce P.R., Fergusson D.M., Woollard G., Abbott R.M., Horwood L.J., Upton J. Urinary catecholamines and plasma hormones predict mood state in rapid cycling bipolar affective disorder. J Affect Disord 1995, 33:233-243.
131. Jung S.H., Park J.M., Moon E., Chung Y.I., Lee B.D., Lee Y.M., Kim J.H., Kim S.Y., Jeong H.J. Delay in the recovery of normal sleep-wake cycle after disruption of the light-dark cycle in mice: a bipolar disorder-prone animal model?. Psychiatry Investig 2014, 11:487-491.
132. Kaladchibachi S.A., Doble B., Anthopoulos N., Woodgett J.R., Manoukian A.S. Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J Circadian Rhythms 2007, 5:3.
133. Kalinichev M., Dawson L.A. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int J Neuropsychopharmacol 2011, 14:1051-1067.
134. Kam J.W., Bolbecker A.R., O'Donnell B.F., Hetrick W.P., Brenner C.A. Resting state EEG power and coherence abnormalities in bipolar disorder and schizophrenia. J Psychiatr Res 2013, 47:1893-1901.
135. Kelly M.P., Logue S.F., Dwyer J.M., Beyer C.E., Majchrowski H., Cai Z., Liu Z., Adedoyin A., Rosenzweig-Lipson S., Comery T.A. The supra-additive hyperactivity caused by an amphetamine-chlordiazepoxide mixture exhibits an inverted-U dose response: negative implications for the use of a model in screening for mood stabilizers. Pharmacol Biochem Behav 2009, 92:649-654.
136. Kim Y.T., Lee S.J., Kim S.H. Effects of the history of conduct disorder on the Iowa Gambling Tasks. Alcohol Clin Exp Res 2006, 30:466-472.
137. Kim M.J., Kwon J.S., Suh S.H., Suh J.K., Jung J., Lee S.N., Kim Y.H., Cho M.C., Oh G.T., Lee K. Transgenic overexpression of translationally controlled tumor protein induces systemic hypertension via repression of Na+, K+-ATPase. J Mol Cell Cardiol 2008, 44:151-159.
138. King D.P., Vitaterna M.H., Chang A.M., Dove W.F., Pinto L.H., Turek F.W., Takahashi J.S. The mouse Clock mutation behaves as an antimorph and maps within the W19H deletion, distal of Kit. Genetics 1997, 146:1049-1060.
139. King D.P., Zhao Y., Sangoram A.M., Wilsbacher L.D., Tanaka M., Antoch M.P., Steeves T.D., Vitaterna M.H., Kornhauser J.M., Lowrey P.L., Turek F.W., Takahashi J.S. Positional cloning of the mouse circadian clock gene. Cell 1997, 89:641-653.
140. Kirshenbaum G.S., Saltzman K., Rose B., Petersen J., Vilsen B., Roder J.C. Decreased neuronal Na+, K+ -ATPase activity in Atp1a3 heterozygous mice increases susceptibility to depression-like endophenotypes by chronic variable stress. Genes Brain Behav 2011, 10:542-550.
141. Kirshenbaum G.S., Clapcote S.J., Petersen J., Vilsen B., Ralph M.R., Roder J.C. Genetic suppression of agrin reduces mania-like behavior in Na+, K+ -ATPase alpha3 mutant mice. Genes Brain Behav 2012, 11:436-443.
142. Kirshenbaum G.S., Burgess C.R., Dery N., Fahnestock M., Peever J.H., Roder J.C. Attenuation of mania-like behavior in Na(+), K(+)-ATPase alpha3 mutant mice by prospective therapies for bipolar disorder: melatonin and exercise. Neuroscience 2014, 260:195-204.
143. Kishi T., Elmquist J.K. Body weight is regulated by the brain: a link between feeding and emotion. Mol Psychiatry 2005, 10:132-146.
144. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996, 93:8455-8459.
145. Koszewska I., Rybakowski J.K. Antidepressant-induced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs. Neuropsychobiology 2009, 59:12-16.
146. Kovacsics C.E., Gould T.D. Shock-induced aggression in mice is modified by lithium. Pharmacol Biochem Behav 2010, 94:380-386.
147. Kozikowski A.P., Gaisina I.N., Yuan H., Petukhov P.A., Blond S.Y., Fedolak A., Caldarone B., McGonigle P. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK-3beta therapies for bipolar disorders. J Am Chem Soc 2007, 129:8328-8332.
148. Kozikowski A.P., Gunosewoyo H., Guo S., Gaisina I.N., Walter R.L., Ketcherside A., McClung C.A., Mesecar A.D., Caldarone B. Identification of a glycogen synthase kinase-3beta inhibitor that attenuates hyperactivity in CLOCK mutant mice. ChemMedChem 2011, 6:1593-1602.
149. Kripke D.F., Mullaney D.J., Atkinson M., Wolf S. Circadian rhythm disorders in manic-depressives. Biol Psychiatry 1978, 13:335-351.
150. Kripke D.F., Nievergelt C.M., Joo E., Shekhtman T., Kelsoe J.R. Circadian polymorphisms associated with affective disorders. J Circadian Rhythms 2009, 7:2.
151. Krishnan K.R. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 2005, 67:1-8.
152. Krishnan V., Nestler E.J. Animal models of depression: molecular perspectives. Curr Top Behav Neurosci 2011, 7:121-147.
153. Kruger S., Sarkar R., Pietsch R., Hasenclever D., Braunig P. Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania - a randomized open-label study. Psychopharmacology 2008, 198:297-299.
154. Kucyi A., Alsuwaidan M.T., Liauw S.S., McIntyre R.S. Aerobic physical exercise as a possible treatment for neurocognitive dysfunction in bipolar disorder. Postgrad Med 2010, 122:107-116.
155. Kulak A., Cuenod M., Do K.Q. Behavioral phenotyping of glutathione-deficient mice: relevance to schizophrenia and bipolar disorder. Behav Brain Res 2012, 226:563-570.
156. Kulak A., Steullet P., Cabungcal J.H., Werge T., Ingason A., Cuenod M., Do K.Q. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxid Redox Signal 2013, 18:1428-1443.
157. Kushner S.F., Khan A., Lane R., Olson W.H. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006, 8:15-27.
158. Lamberty Y., Margineanu D.G., Klitgaard H. Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy Behav 2001, 2:454-459.
159. Lamont E.W., Coutu D.L., Cermakian N., Boivin D.B. Circadian rhythms and clock genes in psychotic disorders. Isr J Psychiatry Relat Sci 2010, 47:27-35.
160. Lavoie J., Hebert M., Beaulieu J.M. Glycogen synthase kinase-3beta haploinsufficiency lengthens the circadian locomotor activity period in mice. Behav Brain Res 2013, 253:262-265.
161. Lee K.W., Woon P.S., Teo Y.Y., Sim K. Genome wide association studies (GWAS) and copy number variation (CNV) studies of the major psychoses: what have we learnt?. Neurosci Biobehav Rev 2012, 36:556-571.
162. Lee S.H., Ripke S., Neale B.M., Faraone S.V., Purcell S.M., Perlis R.H., et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013, 45:984-994.
163. Legrand R., Fielder R. Role of dominance-submission relationships in shock-induced fighting of mice. J Comp Physiol Psychol 1973, 82:501-506.
164. Le-Niculescu H., McFarland M.J., Ogden C.A., Balaraman Y., Patel S., Tan J., Rodd Z.A., Paulus M., Geyer M.A., Edenberg H.J., Glatt S.J., Faraone S.V., Nurnberger J.I., Kuczenski R., Tsuang M.T., Niculescu A.B. Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:134-166.
165. Leussis M.P., Berry-Scott E.M., Saito M., Jhuang H., de Haan G., Alkan O., Luce C.J., Madison J.M., Sklar P., Serre T., Root D.E., Petryshen T.L. The ANK3 bipolar disorder gene regulates psychiatric-related behaviors that are modulated by lithium and stress. Biol Psychiatry 2013, 73:683-690.
166. Li R., el-Mallakh R.S., Harrison L., Changaris D.G., Levy R.S. Lithium prevents ouabain-induced behavioral changes. Toward an animal model for manic depression. Mol Chem Neuropathol 1997, 31:65-72.
167. Li X., Friedman A.B., Zhu W., Wang L., Boswell S., May R.S., Davis L.L., Jope R.S. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry 2007, 61:216-222.
168. Li J., Lu W.Q., Beesley S., Loudon A.S., Meng Q.J. Lithium impacts on the amplitude and period of the molecular circadian clockwork. PLoS ONE 2012, 7:e33292.
169. Li W., Xiong Y., Shang C., Twu K.Y., Hang C.T., Yang J., Han P., Lin C.Y., Lin C.J., Tsai F.C., Stankunas K., Meyer T., Bernstein D., Pan M., Chang C.P. Brg1 governs distinct pathways to direct multiple aspects of mammalian neural crest cell development. Proc Natl Acad Sci USA 2013, 110:1738-1743.
170. Lin Y.F., Huang M.C., Liu H.C. Glycogen synthase kinase 3beta gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J Affect Disord 2013, 147:401-406.
171. Logan R.W., Robledo R.F., Recla J.M., Philip V.M., Bubier J.A., Jay J.J., Harwood C., Wilcox T., Gatti D.M., Bult C.J., Churchill G.A., Chesler E.J. High-precision genetic mapping of behavioral traits in the diversity outbred mouse population. Genes Brain Behav 2013, 12:424-437.
172. Logan R.W., Williams W.P., McClung C.A. Circadian rhythms and addiction: mechanistic insights and future directions. Behav Neurosci 2014, 128:387-412.
173. Lopez-Molina L., Conquet F., Dubois-Dauphin M., Schibler U. The DBP gene is expressed according to a circadian rhythm in the suprachiasmatic nucleus and influences circadian behavior. EMBO J 1997, 16:6762-6771.
174. Machado-Vieira R., Dietrich M.O., Leke R., Cereser V.H., Zanatto V., Kapczinski F., Souza D.O., Portela L.V., Gentil V. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007, 61:142-144.
175. Machado-Vieira R., Soeiro-De-Souza M.G., Richards E.M., Teixeira A.L., Zarate C.A. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J Biol Psychiatry 2014, 15:84-95.
176. Malatynska E., Knapp R.J. Dominant-submissive behavior as models of mania and depression. Neurosci Biobehav Rev 2005, 29:715-737.
177. Malatynska E., Pinhasov A., Crooke J.J., Smith-Swintosky V.L., Brenneman D.E. Reduction of dominant or submissive behaviors as models for antimanic or antidepressant drug testing: technical considerations. J Neurosci Methods 2007, 165:175-182.
178. Malkesman O., Austin D.R., Chen G., Manji H.K. Reverse translational strategies for developing animal models of bipolar disorder. Dis Model Mech 2009, 2:238-245.
179. Malkoff-Schwartz S., Frank E., Anderson B., Sherrill J.T., Siegel L., Patterson D., Kupfer D.J. Stressful life events and social rhythm disruption in the onset of manic and depressive bipolar episodes: a preliminary investigation. Arch Gen Psychiatry 1998, 55:702-707.
180. Mamiya T., Kise M., Morikawa K. Ferulic acid attenuated cognitive deficits and increase in carbonyl proteins induced by buthionine-sulfoximine in mice. Neurosci Lett 2008, 430:115-118.
181. Marston H.M., Young J.W., Martin F.D., Serpa K.A., Moore C.L., Wong E.H., Gold L., Meltzer L.T., Azar M.R., Geyer M.A., Shahid M. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology 2009, 206:699-714.
182. McCarthy M.J., Welsh D.K. Cellular circadian clocks in mood disorders. J Biol Rhythms 2012, 27:339-352.
183. McCarthy M.J., Wei H., Marnoy Z., Darvish R.M., McPhie D.L., Cohen B.M., Welsh D.K. Genetic and clinical factors predict lithium's effects on PER2 gene expression rhythms in cells from bipolar disorder patients. Transl Psychiatry 2013, 3:e318.
184. McClung C.A. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007, 114:222-232.
185. McClung C.A. How might circadian rhythms control mood? Let me count the ways. Biol Psychiatry 2013, 74:242-249.
186. McClung C.A., Sidiropoulou K., Vitaterna M., Takahashi J.S., White F.J., Cooper D.C., Nestler E.J. Regulation of dopaminergic transmission and cocaine reward by the Clock gene. Proc Natl Acad Sci USA 2005, 102:9377-9381.
187. McElroy S.L., Weisler R.H., Chang W., Olausson B., Paulsson B., Brecher M., Agambaram V., Merideth C., Nordenhem A., Young A.H. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010, 71:163-174.
188. McInerney S.J., Kennedy S.H. Review of evidence for use of antidepressants in bipolar depression. Prim Care Companion CNS Disord 2014, 16.
189. Meyendorff E., Lerer B., Moore N.C., Bow J., Gershon S. Methylphenidate infusion in euthymic bipolars: effect of carbamazepine pretreatment. Psychiatry Res 1985, 16:303-308.
190. Miczek K.A., O'Donnell J.M. Intruder-evoked aggression in isolated and nonisolated mice: effects of psychomotor stimulants and l-dopa. Psychopharmacology 1978, 57:47-55.
191. Miczek K.A., Maxson S.C., Fish E.W., Faccidomo S. Aggressive behavioral phenotypes in mice. Behav Brain Res 2001, 125:167-181.
192. Milhiet V., Etain B., Boudebesse C., Bellivier F. Circadian biomarkers, circadian genes and bipolar disorders. J Physiol Paris 2011, 105:183-189.
193. Minassian A., Henry B.L., Geyer M.A., Paulus M.P., Young J.W., Perry W. The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord 2010, 120:200-206.
194. Minassian A., Henry B.L., Young J.W., Masten V., Geyer M.A., Perry W. Repeated assessment of exploration and novelty seeking in the human behavioral pattern monitor in bipolar disorder patients and healthy individuals. PLoS ONE 2011, 6:e24185.
195. Mitchell P.J. Antidepressant treatment and rodent aggressive behaviour. Eur J Pharmacol 2005, 526:147-162.
196. Moore J.D., Hayes C., Hicks R.A. REM sleep deprivation increases preference for novelty in rats. Physiol Behav 1979, 23:975-976.
197. Moore P.J., Little M.A., McSharry P.E., Goodwin G.M., Geddes J.R. Correlates of depression in bipolar disorder. Proc Biol Sci 2014, 281:20132320.
198. Morden B., Mitchell G., Dement W. Selective REM sleep deprivation and compensation phenomena in the rat. Brain Res 1967, 5:339-349.
199. Morissette J., Villeneuve A., Bordeleau L., Rochette D., Laberge C., Gagne B., Laprise C., Bouchard G., Plante M., Gobeil L., Shink E., Weissenbach J., Barden N. Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in Quebec points to a locus of major effect on chromosome 12q23-q24. Am J Med Genet 1999, 88:567-587.
200. Mukherjee B.P., Pradhan S.N. Effects of lithium on foot shock-induced aggressive behavior in rats. Arch Int Pharmacodyn Ther 1976, 222:125-131.
201. Mukherjee S., Coque L., Cao J.L., Kumar J., Chakravarty S., Asaithamby A., Graham A., Gordon E., Enwright J.F., DiLeone R.J., Birnbaum S.G., Cooper D.C., McClung C.A. Knockdown of Clock in the ventral tegmental area through RNA interference results in a mixed state of mania and depression-like behavior. Biol Psychiatry 2010, 68:503-511.
202. Munoz-Montano J.R., Moreno F.J., Avila J., Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 1997, 411:183-188.
203. Mynett-Johnson L., Murphy V., McCormack J., Shields D.C., Claffey E., Manley P., McKeon P. Evidence for an allelic association between bipolar disorder and a Na+, K+ adenosine triphosphatase alpha subunit gene (ATP1A3). Biol Psychiatry 1998, 44:47-51.
204. Nejtek V.A., Kaiser K.A., Zhang B., Djokovic M. Iowa Gambling Task scores predict future drug use in bipolar disorder outpatients with stimulant dependence. Psychiatry Res 2013, 210:871-879.
205. Nestler E.J. Epigenetic mechanisms of depression. JAMA Psychiatry 2014, 71:454-456.
206. Ng F., Dodd S., Berk M. The effects of physical activity in the acute treatment of bipolar disorder: a pilot study. J Affect Disord 2007, 101:259-262.
207. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., Gaynor K., Wang L., LaFrancois J., Feinstein B., Burns M., Krishnamurthy P., Wen Y., Bhat R., Lewis J., Dickson D., Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005, 102:6990-6995.
208. Nunez P.L., Srinivasan R., Westdorp A.F., Wijesinghe R.S., Tucker D.M., Silberstein R.B., Cadusch P.J. EEG coherency. I: statistics, reference electrode, volume conduction, Laplacians, cortical imaging, and interpretation at multiple scales. Electroencephalogr Clin Neurophysiol 1997, 103:499-515.
209. O'Brien W.T., Harper A.D., Jove F., Woodgett J.R., Maretto S., Piccolo S., Klein P.S. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004, 24:6791-6798.
210. O'Brien W.T., Huang J., Buccafusca R., Garskof J., Valvezan A.J., Berry G.T., Klein P.S. Glycogen synthase kinase-3 is essential for beta-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest 2011, 121:3756-3762.
211. O'Donnell K.C., Gould T.D. The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci Biobehav Rev 2007, 31:932-962.
212. O'Donnell B.F., Hetrick W.P., Vohs J.L., Krishnan G.P., Carroll C.A., Shekhar A. Neural synchronization deficits to auditory stimulation in bipolar disorder. NeuroReport 2004, 15:1369-1372.
213. Ochs S.M., Dorostkar M.M., Aramuni G., Schon C., Filser S., Poschl J., Kremer A., Van Leuven F., Ovsepian S.V., Herms J. Loss of neuronal GSK3beta reduces dendritic spine stability and attenuates excitatory synaptic transmission via beta-catenin. Mol Psychiatry 2015, 20:482-489.
214. Oehler J., Jahkel M., Schmidt J. Effect of lithium, carbamazepine, ca-valproate and diazepam on changes in social isolation-induced behavior in mice. Biomed Biochim Acta 1985, 44:1523-1530.
215. Ongur D., Lundy M., Greenhouse I., Shinn A.K., Menon V., Cohen B.M., Renshaw P.F. Default mode network abnormalities in bipolar disorder and schizophrenia. Psychiatry Res 2010, 183:59-68.
216. Orford K., Crockett C., Jensen J.P., Weissman A.M., Byers S.W. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 1997, 272:24735-24738.
217. Ortiz R., Niciu M.J., Lukkahati N., Saligan L.N., Nugent A.C., Luckenbaugh D.A., Machado-Vieira R., Zarate C.A. Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. J Affect Disord 2014, 172C:307-311.
218. Ozburn A.R., Larson E.B., Self D.W., McClung C.A. Cocaine self-administration behaviors in ClockDelta19 mice. Psychopharmacology 2012, 223:169-177.
219. Ozburn A.R., Falcon E., Mukherjee S., Gillman A., Arey R., Spencer S., McClung C.A. The role of clock in ethanol-related behaviors. Neuropsychopharmacology 2013, 38:2393-2400.
220. Ozerdem A., Guntekin B., Tunca Z., Basar E. Brain oscillatory responses in patients with bipolar disorder manic episode before and after valproate treatment. Brain Res 2008, 1235:98-108.
221. Ozerdem A., Guntekin B., Saatci E., Tunca Z., Basar E. Disturbance in long distance gamma coherence in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:861-865.
222. Ozerdem A., Guntekin B., Atagun I., Turp B., Basar E. Reduced long distance gamma (28-48 Hz) coherence in euthymic patients with bipolar disorder. J Affect Disord 2011, 132:325-332.
223. Ozerdema A., Guntekind B., Atagune M.I., Basar E. Brain oscillations in bipolar disorder in search of new biomarkers. Suppl Clin Neurophysiol 2013, 62:207-221.
224. Pandey G.N., Rizavi H.S., Tripathi M., Ren X. Region-specific dysregulation of glycogen synthase kinase-3beta and beta-catenin in the postmortem brains of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2015, 17:160-171.
225. Pedrosa E., Shah A., Tenore C., Capogna M., Villa C., Guo X., Zheng D., Lachman H.M. Beta-catenin promoter ChIP-chip reveals potential schizophrenia and bipolar disorder gene network. J Neurogenet 2010, 24:182-193.
226. Peet M., Peters S. Drug-induced mania. Drug Saf 1995, 12:146-153.
227. Pena C.J., Bagot R.C., Labonte B., Nestler E.J. Epigenetic signaling in psychiatric disorders. J Mol Biol 2014, 426:3389-3412.
228. Perry W., Minassian A., Feifel D., Braff D.L. Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry 2001, 50:418-424.
229. Perry W., Minassian A., Paulus M.P., Young J.W., Kincaid M.J., Ferguson E.J., Henry B.L., Zhuang X., Masten V.L., Sharp R.F., Geyer M.A. A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 2009, 66:1072-1080.
230. Perry W., Minassian A., Henry B., Kincaid M., Young J.W., Geyer M.A. Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Res 2010, 178:84-91.
231. Phiel C.J., Klein P.S. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001, 41:789-813.
232. Pinsonneault J.K., Han D.D., Burdick K.E., Kataki M., Bertolino A., Malhotra A.K., Gu H.H., Sadee W. Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology 2011, 36:1644-1655.
233. Poitou P., Boulu R., Bohuon C. Effect of lithium and other drugs on the amphetamine chlordiazeposice hyperactivity in mice. Experientia 1975, 31:99-101.
234. Polter A., Beurel E., Yang S., Garner R., Song L., Miller C.A., Sweatt J.D., McMahon L., Bartolucci A.A., Li X., Jope R.S. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010, 35:1761-1774.
235. Polyakova M., Stuke K., Schuemberg K., Mueller K., Schoenknecht P., Schroeter M.L. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 2015, 174:432-440.
236. Post R.M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992, 149:999-1010.
237. Postolache T.T., Oren D.A. Circadian phase shifting, alerting, and antidepressant effects of bright light treatment. Clin Sports Med 2005, 24:381-413. xii.
238. Powell S.B., Young J.W., Ong J.C., Caron M.G., Geyer M.A. Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav Pharmacol 2008, 19:562-565.
239. Prasad V., Sheard M.H. Effect of lithium upon desipramine enhanced shock-elicited fighting in rats. Pharmacol Biochem Behav 1982, 17:377-378.
240. Prickaerts J., Moechars D., Cryns K., Lenaerts I., van Craenendonck H., Goris I., Daneels G., Bouwknecht J.A., Steckler T. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 2006, 26:9022-9029.
241. Ralph-Williams R.J., Paulus M.P., Zhuang X., Hen R., Geyer M.A. Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry 2003, 53:352-359.
242. Redrobe J.P., Nielsen A.N. Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania. Behav Brain Res 2009, 198:481-485.
243. Reinhart V., Bove S.E., Volfson D., Lewis D.A., Kleiman R.J., Lanz T.A. Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder. Neurobiol Dis 2015, 77:220-227.
244. Riegel R.E., Valvassori S.S., Elias G., Reus G.Z., Steckert A.V., de Souza B., Petronilho F., Gavioli E.C., Dal-Pizzol F., Quevedo J. Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem Int 2009, 55:491-495.
245. Ripke S., et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011, 43:969-976.
246. Ripperger J.A., Shearman L.P., Reppert S.M., Schibler U. CLOCK, an essential pacemaker component, controls expression of the circadian transcription factor DBP. Genes Dev 2000, 14:679-689.
247. Risbrough V., Ji B., Hauger R., Zhou X. Generation and characterization of humanized mice carrying COMT158 Met/Val alleles. Neuropsychopharmacology 2014, 39:1823-1832.
248. Rivalan M., Ahmed S.H., Dellu-Hagedorn F. Risk-prone individuals prefer the wrong options on a rat version of the Iowa Gambling Task. Biol Psychiatry 2009, 66:743-749.
249. Rock P., Goodwin G., Harmer C., Wulff K. Daily rest-activity patterns in the bipolar phenotype: A controlled actigraphy study. Chronobiol Int 2014, 31:290-296.
250. Rose A.M., Mellett B.J., Valdes R., Kleinman J.E., Herman M.M., Li R., el-Mallakh R.S. Alpha 2 isoform of the Na, K-adenosine triphosphatase is reduced in temporal cortex of bipolar individuals. Biol Psychiatry 1998, 44:892-897.
251. Roussos P., Katsel P., Davis K.L., Bitsios P., Giakoumaki S.G., Jogia J., Rozsnyai K., Collier D., Frangou S., Siever L.J., Haroutunian V. Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia. Arch Gen Psychiatry 2012, 69:7-15.
252. Roybal K., Theobold D., Graham A., DiNieri J.A., Russo S.J., Krishnan V., Chakravarty S., Peevey J., Oehrlein N., Birnbaum S., Vitaterna M.H., Orsulak P., Takahashi J.S., Nestler E.J., Carlezon W.A., McClung C.A. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA 2007, 104:6406-6411.
253. Sachs G.S., Gardner-Schuster E.E. Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatr Scand Suppl 2007, 12:27-34.
254. Sachs G.S., Nierenberg A.A., Calabrese J.R., Marangell L.B., Wisniewski S.R., Gyulai L., Friedman E.S., Bowden C.L., Fossey M.D., Ostacher M.J., Ketter T.A., Patel J., Hauser P., Rapport D., Martinez J.M., Allen M.H., Miklowitz D.J., Otto M.W., Dennehy E.B., Thase M.E. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007, 356:1711-1722.
255. Sarnthein J., Petsche H., Rappelsberger P., Shaw G.L., von Stein A. Synchronization between prefrontal and posterior association cortex during human working memory. Proc Natl Acad Sci USA 1998, 95:7092-7096.
256. Saul M.C., Gessay G.M., Gammie S.C. A new mouse model for mania shares genetic correlates with human bipolar disorder. PLoS ONE 2012, 7:e38128.
257. Saul M.C., Stevenson S.A., Gammie S.C. Sexually dimorphic, developmental, and chronobiological behavioral profiles of a mouse mania model. PLoS ONE 2013, 8:e72125.
258. Scotti M.A., Lee G., Stevenson S.A., Ostromecki A.M., Wied T.J., Kula D.J., Gessay G.M., Gammie S.C. Behavioral and pharmacological assessment of a potential new mouse model for mania. Physiol Behav 2011, 103:376-383.
259. Serretti A., Benedetti F., Mandelli L., Lorenzi C., Pirovano A., Colombo C., Smeraldi E. Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet 2003, 121B:35-38.
260. Shahid M., Walker G.B., Zorn S.H., Wong E.H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009, 23:65-73.
261. Shaldubina A., Einat H., Szechtman H., Shimon H., Belmaker R.H. Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm 2002, 109:433-440.
262. Shaltiel G., Maeng S., Malkesman O., Pearson B., Schloesser R.J., Tragon T., Rogawski M., Gasior M., Luckenbaugh D., Chen G., Manji H.K. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 2008, 13:858-872.
263. Shinozaki G., Potash J.B. New developments in the genetics of bipolar disorder. Curr Psychiatry Rep 2014, 16:493.
264. Sidor M.M., Macqueen G.M. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011, 72:156-167.
265. Sidor M.M., Spencer S.M., Dzirasa K., Parekh P.K., Tye K.M., Warden M.R., Arey R.N., Enwright J.F., Jacobsen J.P., Kumar S., Remillard E.M., Caron M.G., Deisseroth K., McClung C.A. Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol Psychiatry 2015, 5.
266. Silverstone P.H., Pukhovsky A., Rotzinger S. Lithium does not attenuate the effects of D-amphetamine in healthy volunteers. Psychiatry Res 1998, 79:219-226.
267. Sintoni S., Kurtys E., Scandaglia M., Contestabile A., Monti B. Chronic valproic acid administration impairs contextual memory and dysregulates hippocampal GSK-3beta in rats. Pharmacol Biochem Behav 2013, 106:8-15.
268. Sjoholm L.K., Kovanen L., Saarikoski S.T., Schalling M., Lavebratt C., Partonen T. CLOCK is suggested to associate with comorbid alcohol use and depressive disorders. J Circadian Rhythms 2010, 8:1.
269. Snead O.C., Clapcote S.J., Roder J.C., Boulianne G.L. Novel strategies for the development of animal models of refractory epilepsy. Adv Neurol 2006, 97:155-171.
270. Spengler M.L., Kuropatwinski K.K., Schumer M., Antoch M.P. A serine cluster mediates BMAL1-dependent CLOCK phosphorylation and degradation. Cell Cycle 2009, 8:4138-4146.
271. St Onge J.R., Ahn S., Phillips A.G., Floresco S.B. Dynamic fluctuations in dopamine efflux in the prefrontal cortex and nucleus accumbens during risk-based decision making. J Neurosci 2012, 32:16880-16891.
272. Stambolic V., Ruel L., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996, 6:1664-1668.
273. Steullet P., Neijt H.C., Cuenod M., Do K.Q. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 2006, 137:807-819.
274. Steullet P., Cabungcal J.H., Kulak A., Kraftsik R., Chen Y., Dalton T.P., Cuenod M., Do K.Q. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci 2010, 30:2547-2558.
275. Strakowski S.M., Delbello M.P., Adler C.M. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry 2005, 10:105-116.
276. Sudhof T.C., Malenka R.C. Understanding synapses: past, present, and future. Neuron 2008, 60:469-476.
277. Svenson K.L., Gatti D.M., Valdar W., Welsh C.E., Cheng R., Chesler E.J., Palmer A.A., McMillan L., Churchill G.A. High-resolution genetic mapping using the Mouse Diversity outbred population. Genetics 2012, 190:437-447.
278. Sylvia L.G., Dupuy J.M., Ostacher M.J., Cowperthwait C.M., Hay A.C., Sachs G.S., Nierenberg A.A., Perlis R.H. Sleep disturbance in euthymic bipolar patients. J Psychopharmacol 2012, 26:1108-1112.
279. Szabo S.T., Machado-Vieira R., Yuan P., Wang Y., Wei Y., Falke C., Cirelli C., Tononi G., Manji H.K., Du J. Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology 2009, 56:47-55.
280. Tang H., Shen N., Jin H., Liu D., Miao X., Zhu L.Q. GSK-3beta polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis. Mol Neurobiol 2013, 48:404-411.
281. Threadgill D.W., Churchill G.A. Ten years of the Collaborative Cross. Genetics 2012, 190:291-294.
282. Tochigi M., Iwamoto K., Bundo M., Sasaki T., Kato N., Kato T. Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. Neurosci Res 2008, 60:184-191.
283. Torres I.J., DeFreitas C.M., DeFreitas V.G., Bond D.J., Kunz M., Honer W.G., Lam R.W., Yatham L.N. Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. Psychol Med 2011, 41:971-982.
284. Trivedi M.S., Deth R. Redox-based epigenetic status in drug addiction: a potential contributor to gene priming and a mechanistic rationale for metabolic intervention. Front Neurosci 2014, 8:444.
285. Tunca Z., Ozerdem A., Ceylan D., Yalcin Y., Can G., Resmi H., Akan P., Ergor G., Aydemir O., Cengisiz C., Kerim D. Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: The role of lithium. J Affect Disord 2014, 166:193-200.
286. Valvassori S.S., Resende W.R., Lopes-Borges J., Mariot E., Dal-Pont G.C., Vitto M.F., Luz G., de Souza C.T., Quevedo J. Effects of mood stabilizers on oxidative stress-induced cell death signaling pathways in the brains of rats subjected to the ouabain-induced animal model of mania: mood stabilizers exert protective effects against ouabain-induced activation of the cell death pathway. J Psychiatr Res 2015, 65:63-70.
287. van Enkhuizen J., Geyer M.A., Young J.W. Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology 2013, 225:661-674.
288. van Enkhuizen J., Minassian A., Young J.W. Further evidence for ClockDelta19 mice as a model for bipolar disorder mania using cross-species tests of exploration and sensorimotor gating. Behav Brain Res 2013, 249:44-54.
289. van Enkhuizen J., Geyer M.A., Kooistra K., Young J.W. Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. Int J Neuropsychopharmacol 2013, 16:1021-1031.
290. van Enkhuizen J., Geyer M.A., Halberstadt A.L., Zhuang X., Young J.W. Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. J Affect Disord 2014, 155:247-254.
291. van Enkhuizen J., Henry B.L., Minassian A., Perry W., Milienne-Petiot M., Higa K.K., Geyer M.A., Young J.W. Reduced dopamine transporter functioning induces high-reward risk-preference consistent with bipolar disorder. Neuropsychopharmacology 2014, 39:3112-3122.
292. Vassout A., Veenstra S., Hauser K., Ofner S., Brugger F., Schilling W., Gentsch C. NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats. Regul Pept 2000, 96:7-16.
293. Vasudev K., Macritchie K., Geddes J., Watson S., Young A. Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 2006, CD003384.
294. Vitaterna M.H., King D.P., Chang A.M., Kornhauser J.M., Lowrey P.L., McDonald J.D., Dove W.F., Pinto L.H., Turek F.W., Takahashi J.S. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science 1994, 264:719-725.
295. Vitaterna M.H., Ko C.H., Chang A.M., Buhr E.D., Fruechte E.M., Schook A., Antoch M.P., Turek F.W., Takahashi J.S. The mouse Clock mutation reduces circadian pacemaker amplitude and enhances efficacy of resetting stimuli and phase-response curve amplitude. Proc Natl Acad Sci USA 2006, 103:9327-9332.
296. Vucurovic K., Landais E., Delahaigue C., Eutrope J., Schneider A., Leroy C., Kabbaj H., Motte J., Gaillard D., Rolland A.C., Doco-Fenzy M. Bipolar affective disorder and early dementia onset in a male patient with SHANK3 deletion. Eur J Med Genet 2012, 55:625-629.
297. Wang B., Chen D. Evidence for seasonal mania: a review. J Psychiatr Pract 2013, 19:301-308.
298. Whittington M.A., Traub R.D., Kopell N., Ermentrout B., Buhl E.H. Inhibition-based rhythms: experimental and mathematical observations on network dynamics. Int J Psychophysiol 2000, 38:315-336.
299. Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 2006, 21(Suppl 1):S11-S15.
300. Wu J.C., Kelsoe J.R., Schachat C., Bunney B.G., DeModena A., Golshan S., Gillin J.C., Potkin S.G., Bunney W.E. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 2009, 66:298-301.
301. Yang Y., Dieter M.Z., Chen Y., Shertzer H.G., Nebert D.W., Dalton T.P. Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(-/-) knockout mouse. Novel model system for a severely compromised oxidative stress response. J Biol Chem 2002, 277:49446-49452.
302. Yechiam E., Hayden E.P., Bodkins M., O'Donnell B.F., Hetrick W.P. Decision making in bipolar disorder: a cognitive modeling approach. Psychiatry Res 2008, 161:142-152.
303. Yost C., Torres M., Miller J.R., Huang E., Kimelman D., Moon R.T. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996, 10:1443-1454.
304. Young J.W., Dulcis D. Investigating the mechanism(s) underlying switching between states in bipolar disorder. Eur J Pharmacol 2015.
305. Young J.W., Minassian A., Paulus M.P., Geyer M.A., Perry W. A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev 2007, 31:882-896.
306. Young J.W., Goey A.K., Minassian A., Perry W., Paulus M.P., Geyer M.A. The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav 2010, 96:7-15.
307. Young J.W., Henry B.L., Geyer M.A. Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol 2011, 164:1263-1284.
308. Young J.W., van Enkhuizen J., Winstanley C.A., Geyer M.A. Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol 2011, 25:934-943.
309. Zhou D., Lambert S., Malen P.L., Carpenter S., Boland L.M., Bennett V. AnkyrinG is required for clustering of voltage-gated Na channels at axon initial segments and for normal action potential firing. J Cell Biol 1998, 143:1295-1304.
310. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., Hen R. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 2001, 98:1982-1987.